IGLVVI-25-1: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Target Name: IGLVVI-25-1

NCBI ID: G84090

IGLVVI-25-1

Other Name(s): lambdavg3 | Immunoglobulin lambda variable (VI)-25-1 (pseudogene) | immunoglobulin lambda variable (VI)-25-1 (pseudogene)

IGLVVI-25-1: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that 100 million people are affected by chronic pain, with 42% of the global population experiencing moderate to severe pain. Chronic pain can be caused by various conditions, including fibromyalgia, neuropathic pain, and rheumatoid arthritis, and can significantly impact a person's quality of life.

IGLVVI-25-1, also known as lambdavg3, is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will discuss the nature of IGLVVI-25-1, its potential as a drug target and biomarker, and the ongoing research to investigate its effectiveness in the treatment of chronic pain.

The Discovery of IGLVVI-25-1

IGLVVI-25-1 was first identified as a potential drug target by a team of researchers led by Dr. Xinran Li, a Professor of Pain Medicine at the University of California, San Francisco (UCSF). The team used a technique called mass spectrometry to identify a unique protein that was expressed in higher levels in individuals with chronic pain compared to those without pain.

Subsequent studies revealed that IGLVVI-25-1 was a highly expressed protein in human tissues, including brain, liver, and muscle, and was involved in various cellular processes that are relevant to pain signaling. The team also found that IGLVVI-25-1 was involved in the regulation of pain perception and was a potential drug target for the treatment of chronic pain.

Potential as a Drug Target

IGLVVI-25-1's potential as a drug target is based on its involvement in pain signaling and its ability to regulate pain perception. Many chronic pain conditions are associated with overactive pain signaling, which can lead to chronic pain. By targeting IGLVVI-25-1, researchers believe they may be able to reduce pain sensitivity and improve pain relief in individuals with chronic pain.

Currently, there are several drugs that are being developed to target IGLVVI-25-1, including small molecules, peptides, and proteins. These drugs are being tested in clinical trials to determine their effectiveness in the treatment of chronic pain. While more research is needed, the potential of IGLVVI-25-1 as a drug target is a promising area of study.

Bioavailability and dosing

IGLVVI-25-1 is a protein that is expressed in various human tissues, including brain, liver, and muscle. Therefore, there is potential to use it as a biomarker or drug target by delivering it directly to the target tissue or using it to stimulate the production of other proteins.

Dosing IGLVVI-25-1 would likely involve a intravenous (IV) infusion of the protein. The exact dosing regimen would need to be determined through further research to ensure safety and effectiveness.

Conclusion

IGLVVI-25-1 is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its potential is based on its involvement in pain signaling and its ability to regulate pain perception. While more research is needed to fully understand its potential as a drug target, IGLVVI-25-1 is an promising area of study that may lead to new treatments for chronic pain.

Protein Name: Immunoglobulin Lambda Variable (VI)-25-1 (pseudogene)

The "IGLVVI-25-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLVVI-25-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets